Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Sells $2,269,327.66 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) CEO Christopher Richard Anzalone sold 133,333 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total value of $2,269,327.66. Following the completion of the transaction, the chief executive officer now owns 3,773,802 shares in the company, valued at approximately $64,230,110.04. The trade was a 3.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Christopher Richard Anzalone also recently made the following trade(s):

• On Thursday, January 2nd, Christopher Richard Anzalone sold 11,520 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $19.05, for a total value of $219,456.00.
• On Monday, December 23rd, Christopher Richard Anzalone sold 12,563 shares of Arrowhead Pharmaceuticals stock. The shares were sold at an average price of $19.59, for a total value of $246,109.17.
• On Wednesday, December 18th, Christopher Richard Anzalone sold 26,712 shares of Arrowhead Pharmaceuticals stock. The stock was sold at an average price of $21.24, for a total value of $567,362.88.

Arrowhead Pharmaceuticals Stock Up 1.4 %

Arrowhead Pharmaceuticals stock opened at $17.35 on Thursday. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $16.57 and a twelve month high of $35.80. The stock has a 50 day moving average of $19.51 and a two-hundred day moving average of $20.63. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -3.36 and a beta of 0.95.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). As a group, research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on ARWR. HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 12th. Sanford C. Bernstein dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating on the stock in a research note on Friday, November 29th. Piper Sandler dropped their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 27th. Citigroup dropped their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Finally, Chardan Capital restated a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $41.44.

Institutional Trading of Arrowhead Pharmaceuticals

Hedge funds have recently modified their holdings of the business. R Squared Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $38,000. GF Fund Management CO. LTD. acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at approximately $49,000. Van ECK Associates Corp lifted its holdings in shares of Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company’s stock valued at $56,000 after buying an additional 1,250 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 788 shares during the period. Finally, KBC Group NV lifted its holdings in shares of Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 1,644 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.